Polycyclic compound and application thereof

By developing a compound with excellent proliferation inhibitory activity and YAP-TEAD inhibitory activity, the problem of Hippo signaling pathway regulation, especially the cancer problem caused by abnormal activity of YAP/TEAD, effective treatment of cancer and reduced side effects.

CN118930522APending Publication Date: 2024-11-12TYK MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311480779.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2023-11-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate the Hippo signaling pathway, especially cancer and proliferative diseases caused by abnormal activity of YAP/TEAD, and existing treatment methods have problems with limited efficacy and side effects.

Method used

A structurally novel compound with excellent proliferation inhibitory activity and YAP-TEAD inhibitory activity was developed, and the compound was prepared by structural optimization for the prevention and treatment of cancer, especially the regulation of diseases caused by Hippo pathway dysregulation.

Benefits of technology

This compound significantly inhibits the activity of the YAP-TEAD complex, has excellent pharmacokinetic properties and is able to penetrate the blood-brain barrier, providing an effective treatment for cancer and reducing the occurrence of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930522A_ABST
    Figure CN118930522A_ABST
Patent Text Reader

Abstract

The invention relates to a polycyclic compound and application thereof. Specifically, the compound disclosed by the invention has a structure as shown in a formula I, and the definitions of all groups and substituent groups are described in the specification. The invention also discloses a preparation method of the compound and application of the compound in preventing and / or treating proliferative diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and specifically to a polycyclic compound for regulating the Hippo pathway, a preparation method and use thereof, which is mainly used for the treatment or prevention of proliferative diseases (such as cancer), especially for regulating and treating related diseases caused by abnormal activity of YAP / TEAD. Background Art

[0002] The Hippo pathway is essentially composed of a core kinase cascade that contains the Ste-20 family of protein kinases MST1-2, the scaffolding protein Salvador and the large tumor suppressor kinase LATS1-2, and the inhibitory transcriptional coactivators YAP (Yes1-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif). YAP and TAZ are the main effectors of the Hippo signaling pathway, which act as transcription factors together with TEAD (transcription-enhanced association domain) in the nucleus to increase the expression of target genes such as CTGF (connective tissue growth factor), CYR61, etc. The Hippo pathway is an important regulator of cell growth, proliferation and migration. TEAD transcription factors are located at the core of the Hippo pathway and are essential for regulating organ growth and wound repair. Dysregulation of TEAD and its regulatory cofactor Yes-associated protein (YAP) has been implicated in many human cancers and hyperproliferative pathological processes, and dysregulation of this pathway is frequently detected in human cancers. Like TEAD proteins, YAP and TAZ activation have been identified in many human tumors and are essential for tumor initiation, progression, and metastasis. For example, YAP expression is elevated in patients with breast, ovarian, colon, liver, and pancreatic cancers and is associated with decreased survival. Consistent with this, activation or overexpression of YAP or TAZ enhances TEAD-dependent gene expression (e.g., CCN1, CTGF, ITGB2, and Birc5 / survivin) and promotes cell proliferation and migration in many cell types. In contrast, blocking signals or interventions that prevent the expression of many mitogenic TEAD target genes that form the YAP / TAZ-TEAD complex can significantly reduce cell proliferation and oncogenic transformation activity. In addition, the Hippo pathway also cross-talks with other signaling pathways such as Wnt, Notch, Hedgehog, and MAPK, thereby affecting a variety of biological functions, and its dysfunction may be involved in many human diseases in addition to cancer. Therefore, the YAP-TEAD complex is a promising therapeutic target. Summary of the invention

[0003] The object of the present invention is to provide a compound represented by formula I and a preparation method thereof and use thereof in preventing or treating proliferative diseases.

[0004] In a first aspect of the present invention, there is provided a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof,

[0005]

[0006] in,

[0007] X1, X2, X3, and X4 are each independently selected from the following group: CR, N;

[0008] R is independently selected from the group consisting of H, halogen, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl;

[0009] A is selected from the following group:

[0010] B is selected from the following group:

[0011] L is selected from the group consisting of NR4, O, S, Se, sulfoxide, sulfone, CR2R3;

[0012] R1 is selected from the group consisting of H, CF3, CF2H, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethoxy, SF5, tert-butyl;

[0013] R2 is independently selected from the following group: H, halogen, CN, NH2, hydroxyl, ester group, urea group, carbamate group, amide group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, among which NH2, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 The hydrogen in the cycloalkoxy, aryl and heteroaryl groups can be arbitrarily substituted, and the substituents are halogen, CN, NH2, hydroxyl, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, or R2 and the structure to which it is connected form a 3-7 membered ring, or different R2s form a 3-7 membered ring;

[0014] R3, R4, and R5 are each independently selected from the group consisting of H, F, methyl, and CN;

[0015] m is each independently selected from the following group: 0, 1, 2, 3, 4, 5, 6.

[0016] In another preferred embodiment, the "aryl" is each independently C 6-10 Aryl.

[0017] In another preferred embodiment, the “heteroaryl” is each independently a 5-10 membered heteroaryl group containing 1, 2, 3 or 4 heteroatoms selected from N, O or S.

[0018] In another preferred embodiment, X1 is N.

[0019] In another preferred embodiment, X2 is CH.

[0020] In another preferred embodiment, X3 is CH.

[0021] In another preferred embodiment, X4 is CH.

[0022] In another preferred embodiment, B is selected from the following group:

[0023] R2, R3, R4, and R5 are H;

[0024] m is 0.

[0025] In another preferred embodiment, m is selected from the following group: 0, 1, 2, 3.

[0026] In another preferred embodiment, the compound is as shown in Formula II, Formula III, or Formula IV:

[0027]

[0028] wherein X2, A, B, L, and R1 are as defined above.

[0029] In another preferred embodiment,

[0030] A is selected from the following group:

[0031] B is selected from the following group:

[0032] R2, R3, R4, R5 and m are as defined above.

[0033] In another preferred embodiment, B is selected from the following group:

[0034] R2, R3, R4, R5 and m are as defined above.

[0035] The second aspect of the present invention provides a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein the compound is selected from the following group:

[0036]

[0037]

[0038]

[0039] The third aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound described in the first aspect of the present invention or the second aspect of the present invention or a pharmaceutically acceptable salt, solvate or prodrug thereof.

[0040] The fourth aspect of the present invention provides a use of the pharmaceutical composition according to the third aspect of the present invention for preparing a drug for preventing and / or treating a proliferative disease.

[0041] In another preferred embodiment, the proliferative disease is cancer.

[0042] In another preferred embodiment, the cancer is selected from the group consisting of brain glioma, prostate cancer, lung squamous cell carcinoma, breast cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, and squamous cell carcinoma.

[0043] The fifth aspect of the present invention provides a use of the pharmaceutical composition according to the third aspect of the present invention for preparing a drug, wherein the drug is used for a use selected from the group consisting of:

[0044] 1) Prevent and / or treat diseases caused by abnormal activity of YAP / TEAD;

[0045] 2) Prevent and / or treat diseases caused by Hippo pathway dysregulation;

[0046] 3) Prevent and / or treat diseases related to YAP or TAZ or YAP / TAZ or TEAD or YAP / TEAD or YAP / TAZ / TEAD dysregulation.

[0047] In another preferred embodiment, the drug is used to prevent and / or treat related diseases caused by YAP / TEAD or YAP / TAZ / TEAD disorders.

[0048] In another preferred embodiment, the related disease caused by the abnormal activity of YAP / TEAD is cancer.

[0049] In another preferred embodiment, the disease related to the Hippo pathway disorder is cancer.

[0050] In another preferred embodiment, the related disease caused by YAP or TAZ or YAP / TAZ or TEAD or YAP / TEAD or YAP / TAZ / TEAD disorder is cancer.

[0051] In another preferred embodiment, the TEAD is selected from the following group: TEAD1, TEAD2, TEAD3, TEAD4, preferably TEAD1.

[0052] The sixth aspect of the present invention provides a combination of the compound according to the first aspect or the second aspect of the present invention or a pharmaceutically acceptable salt, solvate or prodrug thereof and a second drug for preventing and / or treating cancer;

[0053] The second drug is selected from the group consisting of ERK inhibitors, MEK inhibitors, KRAS inhibitors, BRAF inhibitors, EGFR inhibitors, Wnt inhibitors, and PD-1 inhibitors.

[0054] In another preferred embodiment, the ERK inhibitor is selected from the following group: AZD0364, Ulixertinib, or a combination thereof.

[0055] In another preferred embodiment, the MEK inhibitor is selected from the following group: cobimetinib, binimetinib, or a combination thereof.

[0056] In another preferred embodiment, the KRAS inhibitor is selected from the following group: Adagrasib (MRTX849), JNJ-74699157 (ARS-3248), JAB-3312, or a combination thereof.

[0057] In another preferred embodiment, the BRAF inhibitor is selected from the group consisting of sorafenib, regorafenib, or a combination thereof.

[0058] In another preferred embodiment, the EGFR inhibitor is selected from the following group: osimertinib, dacomitinib, gefitinib, or a combination thereof.

[0059] In another preferred embodiment, the Wnt inhibitor is selected from the following group: IWR-1, ETC-159, or a combination thereof.

[0060] In another preferred embodiment, the PD-1 inhibitor is selected from the group consisting of nivolumab, atezolizumab, pembrolizumab, or a combination thereof.

[0061] In another preferred embodiment, the cancer is selected from the group consisting of brain glioma, prostate cancer, lung squamous cell carcinoma, breast cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, and squamous cell carcinoma.

[0062] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 Thermal shifts of recombinant human TEAD1, TEAD2, TEAD3, and TEAD4 proteins alone or in the presence of T18. DETAILED DESCRIPTION

[0064] After long-term and in-depth research, the inventors prepared a novel compound of formula I with excellent proliferation inhibition activity and excellent YAP-TEAD inhibition activity through structural optimization. On this basis, the inventors completed the present invention.

[0065] the term

[0066] In the present invention, unless otherwise specified, the terms used have the general meanings well known to those skilled in the art.

[0067] In the present invention, the term "halogen" refers to F, Cl, Br or I.

[0068] In the present invention, “C 1-6 The term "alkyl" refers to a straight or branched chain alkyl group containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, or the like.

[0069] In the present invention, the term "C 2-6 The term "alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including but not limited to ethenyl, propenyl, butenyl, isobutenyl, pentenyl and hexenyl.

[0070] In the present invention, the term "C 2-6 The term "alkynyl" refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms and containing one triple bond, including but not limited to ethynyl, propynyl, butynyl, isobutynyl, pentynyl and hexynyl.

[0071] In the present invention, the term "C 3-6 The "cycloalkyl" group includes a group selected from the group consisting of: C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl, C 3-6 Cycloalkynyl.

[0072] In the present invention, the term "C 3-6 The term "cycloalkyl" refers to a cyclic alkyl group having 3 to 6 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0073] In the present invention, the term "C 5-8 The term "bridged cyclic group" refers to a cyclic alkyl group having a bridge and 5 to 8 carbon atoms, including but not limited to wait.

[0074] In the present invention, the term "C 1-6 "Alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy. Preferably, C 1-4 Alkoxy.

[0075] In the present invention, the term "heterocyclic group" refers to a 4-8 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O and S, including (but not limited to) the following groups:

[0076] In the present invention, the term "aromatic ring" or "aryl group" has the same meaning, preferably "C 6-10 The term "C 6-10 The term "aryl" refers to an aromatic ring group having 6 to 10 carbon atoms and containing no heteroatoms in the ring, such as phenyl, naphthyl, etc.

[0077] In the present invention, the term "aromatic heterocycle" or "heteroaryl" has the same meaning and refers to a heteroaromatic group containing one to multiple heteroatoms. For example, "C3-C10 heteroaryl" refers to an aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen and 3 to 10 carbon atoms. Non-limiting examples include: furanyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.

[0078] In the present invention, the term "sulfoxide" refers to a

[0079] In the present invention, the term "sulfone" refers to a

[0080] In the present invention, the term "ester group" refers to the structure

[0081] In the present invention, the term "urea group" refers to a structure

[0082] In the present invention, the term "carbamate group" refers to a structure

[0083] In the present invention, the term "amide group" refers to the structure

[0084] In the present invention, the term "halo" means substituted with halogen.

[0085] In the present invention, the term "deuterated" means substituted with deuterium.

[0086] In the present invention, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is the substituent described above, or the substituent appearing in each embodiment. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It should be understood by those skilled in the art that the combination of substituents contemplated by the present invention is those stable or chemically feasible combinations. The substituents include, for example (but not limited to): halogen, hydroxyl, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclic radical, aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amino, C1-C6 alkoxy, C1-C10 sulfonyl, etc.

[0087] In the present invention, the term 1-6 refers to 1, 2, 3, 4, 5 or 6. Other similar terms independently have similar meanings. The term "plurality" refers to 2-6, such as 2, 3, 4, 5 or 6.

[0088] It should be understood that when a group is present in multiple different positions of a compound at the same time, its definition at each position is independent of each other and may be the same or different. That is, the term "selected from the following group:" has the same meaning as the term "each independently selected from the following group:".

[0089] Compounds and methods of preparation

[0090] The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof,

[0091]

[0092] wherein each group is as defined above.

[0093] In another preferred embodiment, in the compound, any one of R1, X1, X2, X3, X4, L, A, and B is independently a corresponding group in the specific compound.

[0094] In another preferred embodiment, the compound is the specific compound shown in the present invention.

[0095] As used herein, the term "pharmaceutically acceptable salt" refers to a salt formed by a compound of the present invention and an acid or base that is suitable for use as a drug. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts is a salt formed by a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid.

[0096] Another preferred salt is a salt of the compound of the present invention and a base, such as an alkali metal salt (e.g., sodium salt or potassium salt), an alkaline earth metal salt (e.g., magnesium salt or calcium salt), an ammonium salt (e.g., lower alkanolammonium salt and other pharmaceutically acceptable amine salts), for example, methylamine salt, ethylamine salt, propylamine salt, dimethylamine salt, trimethylamine salt, diethylamine salt, triethylamine salt, tert-butylamine salt, ethylenediamine salt, hydroxyethylamine salt, dihydroxyethylamine salt, trihydroxyethylamine salt, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0097] The term "solvate" refers to a complex in which the compound of the present invention is coordinated with solvent molecules to form a specific ratio.

[0098] In addition, the compounds of the present invention also include prodrugs of the compounds shown in Formula I. The term "prodrug" includes a compound that can be biologically active or inactive, and when taken by an appropriate method, it undergoes metabolism or chemical reactions in the human body and is converted into a class of compounds of Formula I, or a salt or solution composed of a compound of Formula I. The prodrug includes (but is not limited to) carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amino compound, carbamate, azo compound, phosphoramide, glucoside, ether, acetal and the like forms of the compound.

[0099] It should be understood that the compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in the specification or known in the art, and such combination can be easily performed by those skilled in the art to which the present invention belongs.

[0100] Typically, the raw materials and reagents used in the process for preparing the compounds of the present invention can be purchased through commercial channels unless otherwise specified.

[0101] Pharmaceutical compositions and methods of administration

[0102] The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof.

[0103] Since the compounds of the present invention have excellent anti-tumor activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate tumor-related diseases.

[0104] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 10-1000 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.

[0105] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0106] The pharmaceutical composition is in the form of injection, capsule, tablet, pill, powder or granule.

[0107] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administrations include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0108] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0109] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.

[0110] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.

[0111] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0112] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances.

[0113] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0114] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0115] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as anti-tumor drugs).

[0116] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0117] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill of a skilled physician.

[0118] Compared with the prior art, the present invention has the following main advantages:

[0119] (1) The compound has excellent proliferation inhibition activity;

[0120] (2) The compound has excellent YAP-TEAD inhibitory activity;

[0121] (3) The compound has excellent pharmacokinetic properties;

[0122] (4) The compound has excellent blood-brain barrier (BBB) ​​permeability.

[0123] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0124] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0125] Example 1

[0126] The compound synthesized by the present invention:

[0127]

[0128] The synthetic route is as follows:

[0129]

[0130] The experimental process is as follows:

[0131] (1) Synthesis of T2-2

[0132] T2-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eqiv), and 50 ml of ultra-dry 1,4-dioxane were added sequentially into a microwave tube, and the mixture was reacted at 150°C under microwave for 45 minutes.

[0133] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography using PE 100%, PE:EA=500:1 to obtain 1.3 g of T2-2.

[0134] (2) Synthesis of T2-3

[0135] T2-2 (1.3 g, 3.55 mmol, 1.0 eq), pinacol borate (1.32 g, 4.26 mmol, 1.2 eqiv), potassium carbonate (981.2 mg, 7.1 mmol, 2.0 eqiv) water / 1,4-dioxane (1 / 10) (1.5 mL / 15 mL), Pd(dppf)Cl2 (129.75 mg, 0.178 mmol, 5% eq) were added to a 100 mL single-mouth bottle in sequence. After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and diluted with EA, filtered through diatomaceous earth, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by spinning through a column to obtain 1.4 g of T2-3 (light yellow solid).

[0136] (3) Synthesis of T2-4

[0137] Dissolve T2-3 (1.4 g) in ethanol (15 mL), add triphenylphosphine rhodium chloride (210 mg, 20%), and react under high-pressure hydrogen for 24 h. If the raw material is not completely reacted, pass through the column to obtain T2-4 1.4 g (white solid)

[0138] (4) Synthesis of T2-5

[0139] T2-4 (1.5 g, 3.29 mmol, 1.0 eq), T2-4a (1.72 g, 8.23 ​​mmol, 2.5 eq), NaHCO3 (1.24 g, 14.81 mmol, 4.5 eq) Pd(OAC)2 (73.7 mg, 0.33 mmol, 0.1 eq) and PCy3 (184.53 mg, 0.66 mmol, 0.2 eq) were added to the reaction flask, and the solvent was 1,4-dioxane / EtOH / water (7:2:1) (11.9 ml / 3.4 ml / 1.7 ml). After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed, the mixture was cooled to room temperature and 20 mL of water was added. The mixture was extracted with ethyl acetate (25 mL*3). The organic layers were combined and washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and dried by column to obtain 1.53 g of product T2-5.

[0140] (5) Synthesis of Compound T2-6

[0141] Compound T2-5 (1.53 g) was added to DCM (10 ml), and then HCl / dioxane (25 mL, 4 M) was added, and then reacted at room temperature overnight. After direct spin drying, 1.6 g of white solid T2-6 was obtained.

[0142] (6) Synthesis of Compound T2

[0143] Compound T2-6 (1.6 mg, 4 mmol, 1.0 eq), triethylamine (1.2 g, 12 mmol, 3.0 eq), and DCM (12 ml) were added to a reaction flask, and then a DCM solution (6 ml) of acryloyl chloride (397.3 mg, 4.4 mmol, 1.1 eq) was added dropwise at zero degree, and stirred at room temperature overnight. The solution was washed with 0.1 N HCl, and then EA was added for extraction, and then petroleum ether and EA were used for column chromatography to purify 452 mg of T2 (white solid).

[0144] 1 H NMR(400MHz,Chloroform-d)δ8.32(d,J=2.2Hz,1H),7.72(s,1H),7.62-7.48(m,6H),6.63(dd,J=16.8,10.6Hz,1H),6.46-6.26(m,2H),5.74(dd,J=1 0.5,1.9Hz,1H),4.92(d,J=13.4Hz,1H),4.24-4.16(m,1H),3.96(s,3H),3 .24(t,J=12.8Hz,1H),2.95-2.73(m,2H),2.07-1.98(m,2H),1.73(s,2H).

[0145] Referring to the synthesis method of compound T2, the following compounds were synthesized:

[0146]

[0147]

[0148]

[0149] Example 2

[0150] Compound T18 synthesized by the present invention:

[0151]

[0152] The synthetic route is as follows:

[0153]

[0154] The experimental process is as follows:

[0155] (1) Synthesis of T18-2

[0156] T18-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eq) and 50 ml of ultra-dry 1,4-dioxane were added sequentially into a microwave tube, and the mixture was reacted at 150°C under microwave for 45 minutes.

[0157] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography using a mobile phase (PE 100%, PE:EA = 500:1) to obtain 1.3 g of T18-2.

[0158] (2) Synthesis of T18-3

[0159] T18-2 (1.0 g, 3.17 mmol, 1.0 eq), S1 (1.0 g, 3.80 mmol, 1.2 eq), potassium carbonate (780 mg, 6.34 mmol, 2.0 eq) water / 1,4-dioxane (1 / 10) (1 mL / 10 mL), Pd(dppf)Cl2 (200 mg, 0.317 mmol, 10% eq) were added to a 100 mL single-mouth bottle in sequence. After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and diluted with EA, filtered through diatomaceous earth, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by spinning through a column to obtain 900 mg T18-3 (light yellow liquid).

[0160] (3) Synthesis of T18-4

[0161] Dissolve T18-3 (900 mg) in ethanol (10 mL), add triphenylphosphine rhodium chloride (210 mg, 20%), react at 60 ° C under high pressure hydrogen conditions for 16 h, filter through diatomaceous earth pad to remove triphenylphosphine rhodium chloride after the reaction, and pass through a column to obtain T18-4820 mg (red solid)

[0162] (4) Synthesis of T18-5

[0163] T18-4 (800 mg, 1.855 mmol, 1.0 eq), S2 (967 mg, 4.63 mmol, 2.5 eq), NaHCO3 (710 mg, 8.34 mmol, 4.5 eq), Pd(OAC)2 (41 mg, 0.1855 mmol, 0.1 eq) and PCy3 (103.6 mg, 0.371 mmol, 0.2 eq) were added to the reaction flask, and the solvent was added with 1,4-dioxane / EtOH / water (7:2:1) (11.9 ml / 3.4 ml / 1.7 ml). After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed, the mixture was cooled to room temperature and 20 mL of water was added. The mixture was extracted with ethyl acetate (25 ml*3). The organic layers were combined and washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and dried by spinning through a column to obtain 500 mg of product T18-5.

[0164] (5) Synthesis of Compound T18-6

[0165] Compound T18-5 (500 mg) was added to DCM (10 ml), and then HCl / dioxane (10 mL, 4 M) was added, and then reacted at room temperature overnight. After direct spin drying, 570 mg of a white solid was obtained.

[0166] (6) Synthesis of Compound T18

[0167] Compound T18-6 (570 mg, 1.47 mmol, 1.0 eq), triethylamine (445 mg, 4.4 mmol, 3.0 eq), and DCM (5 ml) were added to a reaction flask, and then a DCM solution (2 ml) of acryloyl chloride (145 mg, 1.61 mmol, 1.1 eq) was added dropwise at zero degree, and stirred at room temperature overnight. The solution was washed with 0.1 N HCl, and then EA was added for extraction, and then 130 mg of T18 (white solid) was purified by column chromatography using petroleum ether and EA. The obtained solid was subjected to chiral separation. 15 mg of T19 structure and 15 mg of T20 were obtained.

[0168] Referring to the synthesis method of compound T18, the following compounds were synthesized:

[0169]

[0170]

[0171]

[0172]

[0173] Example 3

[0174] Compound T22 synthesized by the present invention:

[0175]

[0176] The synthetic route is as follows:

[0177]

[0178] The experimental process is as follows:

[0179] (1) Synthesis of T22-2

[0180] T22-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eq), 50 ml of ultra-dry 1,4-dioxane were added to the microwave tube in sequence, and the mixture was reacted at 150°C for 45 minutes under microwave. After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was purified by column chromatography using PE 100%, PE:EA=500:1 to obtain 1.3 g of T22-2.

[0181] (2) Synthesis of T22-3

[0182] T22-2 (1.0 g, 3.17 mmol, 1.0 eq), T22-2b (1.0 g, 3.80 mmol, 1.2 eq), potassium carbonate (780 mg, 6.34 mmol, 2.0 eq) water / 1,4-dioxane (1 / 10) (1 mL / 10 mL), Pd(dppf)Cl2 (200 mg, 0.317 mmol, 10% eq) were added to a 100 mL single-mouth bottle in sequence. After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and diluted with EA, filtered through diatomaceous earth, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by suction and passed through a column to obtain 900 mg T22-3 (light yellow liquid).

[0183] (3) Synthesis of T22-4

[0184] T22-3 (900 mg) was dissolved in ethanol (10 mL), triphenylphosphine rhodium chloride (210 mg, 20%) was added, and the mixture was reacted at 60 ° C for 16 h under high pressure hydrogen conditions. After the reaction, triphenylphosphine rhodium chloride was removed by diatomaceous earth pad filtration, and T22-41.0 g (red solid) was obtained by column chromatography.

[0185] (4) Synthesis of T22-5

[0186] T22-4 (1.0 g, 2.19 mmol, 1.0 eq), T22-4b (370 mg, 4.38 mmol, 2.0 eq), K3PO4 (140 mg, 6.59 mmol, 3.0 eq) Pd(OAC)2 (50 mg, 0.219 mmol, 0.1 eq) and PCy3 (123 mg, 0.438 mmol, 0.2 eq) were added to the reaction bottle, and the solvent was added with toluene / water (10:1) (10 ml / 1 ml). After nitrogen replacement three times, the oil bath was placed in an oil bath and heated to 100 degrees for 16 hours. After the reaction was completed, the temperature was lowered to room temperature and filtered, the filtrate was spin-dried, and column chromatography was performed to obtain 1.0 g of product T22-5.

[0187] (5) Synthesis of Compound T22-6

[0188] Compound T22-5 (1.0 g) was added to DCM (10 ml), and then HCl / dioxane (10 mL, 4 M) was added, and then reacted at room temperature overnight. After direct spin drying, 1.0 g of white solid was obtained with a content of 78%.

[0189] (6) Synthesis of Compound T22

[0190] Compound T22-6 (1.0 g, 2.7 mmol, 1.0 eq), triethylamine (840 mg, 8.1 mmol, 3.0 eq), and DCM (10 ml) were added to a reaction flask and stirred for 10 min under an ice bath. Then, a DCM solution (5 ml) of acryloyl chloride (274 mg, 2.97 mmol, 1.1 eq) was added dropwise at zero degrees and stirred overnight at room temperature. The solution was washed with 0.1 N HCl, and then EA was added for extraction, and then 200 mg of T22 (white solid) was purified by column chromatography using petroleum ether and EA.

[0191] 1H NMR(400MHz,Chloroform-d)δ8.00(d,J=2.3Hz,1H),7.52(d,J=8.7Hz,2H),7.38(d,J=8.7Hz,2H),7.15(d,J= 2.4Hz,1H),6.62(dd,J=16.8,10.6Hz,1H),6.33(dd,J=16.8,1.9Hz,1H),6.23(s,1H),5.73(dd,J=10.5,1.9H z,1H),4.89(d,J=13.4Hz,1H),4.17(d,J=13.7Hz,1H),3.21(t,J=12.9Hz,1H),2.88-2.66(m,2H),1.95(d,J= 13.4Hz,2H),1.85(tt,J=8.5,5.1Hz,1H),1.02-0.93(m,2H),0.92-0.77(m,2H),0.66(dt,J=6.7,4.7Hz,2H).

[0192] Referring to the synthesis method of compound T22, the following compounds were synthesized:

[0193]

[0194]

[0195] Example 4

[0196] Compound T24 synthesized by the present invention:

[0197]

[0198] The synthetic route is as follows:

[0199]

[0200] The experimental process is as follows:

[0201] (1) Synthesis of T24-2

[0202] T24-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eq) and 50 ml of ultra-dry 1,4-dioxane were added sequentially into a microwave tube, and the mixture was reacted at 150°C under microwave for 45 minutes.

[0203] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography using PE 100%, PE:EA=500:1 to obtain 1.3 g of T24-2.

[0204] (2) Synthesis of T24-3

[0205] T24-2 (1.0 g, 3.17 mmol, 1.0 eq), S1 (1.0 g, 3.80 mmol, 1.2 eq), potassium carbonate (780 mg, 6.34 mmol, 2.0 eq) water / 1,4-dioxane (1 / 10) (1 mL / 10 mL), Pd(dppf)Cl2 (200 mg, 0.317 mmol, 10% eq) were added to a 100 mL single-mouth bottle in sequence. After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and diluted with EA, filtered through diatomaceous earth, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by spinning through a column to obtain 900 mg T24-3 (light yellow liquid).

[0206] (3) Synthesis of T24-4

[0207] T24-3 (900 mg) was dissolved in ethanol (10 mL), triphenylphosphine rhodium chloride (210 mg, 20%) was added, and the mixture was reacted at 60 ° C for 16 h under high pressure hydrogen conditions. After the reaction, triphenylphosphine rhodium chloride was removed by diatomaceous earth pad filtration, and T24-41.0 g (red solid) was obtained by column chromatography.

[0208] (4) Synthesis of T24-5

[0209] T24-4 (900 mg, 1.98 mmol, 1.0 eq), T24-4a (338 mg, 3.01 mmol, 1.5 eq), K2CO3 (818 mg, 5.94 mmol, 3.0 eq), Pd2(dba)3 (180 mg, 0.198 mmol, 0.1 eq) and PCy3 (123 mg, 0.438 mmol, 0.2 eq) were added to the reaction bottle, and the solvent was added with toluene / water (10:1) (18 ml / 1.8 ml). After nitrogen replacement three times, the oil bath was placed in an oil bath and heated to 100 degrees for 16 hours. After the reaction was completed, the temperature was cooled to room temperature and filtered, the filtrate was spin-dried, and column chromatography was performed to obtain 1.0 g of product T24-5.

[0210] (5) Synthesis of T24-6

[0211] T24-5 (1.0 g) was added to MeOH (10 ml), and then Pd(OH)2 (100 mg, 10%) was added to replace the hydrogen and reacted at room temperature overnight. After the reaction was completed, the palladium catalyst was removed by suction and 500 mg of T24-6 was obtained by column chromatography.

[0212] (6) Synthesis of T24-7

[0213] T24-6 (500 mg) was added to DCM (5 ml), and HCl / dioxane (5 ml, 4 M) was added. The mixture was stirred at room temperature for 3 h. After the reaction was completed, the mixture was directly spin-dried to obtain 400 mg of product T24-7.

[0214] (7) Synthesis of Compound T24

[0215] Compound 24-7 (400 mg, 1.02 mmol, 1.0 eq), triethylamine (310 mg, 3.07 mmol, 3.0 eq), and DCM (4 ml) were added to a reaction flask and stirred for 10 min under an ice bath. Then, a DCM solution (2 ml) of acryloyl chloride (101 mg, 1.12 mmol, 1.1 eq) was added dropwise at zero degrees and stirred at room temperature for 3 h. After the reaction, the solution was washed with 0.1 N HCl, and then EA was added for extraction. Then, petroleum ether and EA were used for column chromatography to purify 150 mg of T24 (white solid).

[0216] 1 H NMR(400MHz,Chloroform-d)δ8.07(d,J=2.3Hz,1H),7.53(d,J=8.4Hz,2H),7.41(d,J=8.4Hz,2H),7.3 4(d,J=2.3Hz,1H),6.63(dd,J=16.8,10.5Hz,1H),6.38-6.29(m,2H),5.73(dd,J=10.5,1.9Hz,1H),4.8 9(d,J=13.2Hz,1H),4.17(d,J=13.9Hz,1H),3.21(t,J=13.1Hz,1H),3.01-2.78(m,3H),2.06(t,J=9.2H z,2H),1.97(d,J=13.8Hz,2H),1.82(td,J=9.0,8.5,5.0Hz,2H),1.77-1.66(m,4H),1.58-1.51(m,2H).

[0217] Referring to the synthesis method of compound T24, the following compounds were synthesized:

[0218]

[0219] Example 5

[0220] Compound T14 synthesized by the present invention:

[0221]

[0222] The synthetic route is as follows:

[0223]

[0224] The experimental process is as follows:

[0225] (1) Synthesis of T14-2

[0226] T24-4 (500 mg, 1.09 mmol, 1.0 eq), T14-1 (298 mg, 2.19 mmol, 2.0 eq), K3PO4 (700 mg, 3.29 mmol, 3.0 eq), Pd(OAC)2 (25 mg, 0.109 mmol, 0.1 eq) and PCy3 (60 mg, 0.219 mmol, 0.2 eq) were added to the reaction bottle, and the solvent was added with toluene / water (10:1) (10 ml / 1 ml). After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 100 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and filtered, the filtrate was spin-dried, and 400 mg of product T14-2 was obtained by column chromatography.

[0227] (2) Synthesis of T14-3

[0228] Compound T14-2 (400 mg) was added to DCM (5 ml), and then HCl / dioxane (5 mL, 4 M) was added, and then reacted at room temperature overnight. After direct spin drying, 500 mg of T14-3 was obtained as a white solid.

[0229] (3) Synthesis of Compound T14

[0230] Compound T14-3 (500 mg, 1.2 mmol, 1.0 eq), triethylamine (360 mg, 3.6 mmol, 3.0 eq), and DCM (5 ml) were added to a reaction flask and stirred for 10 min under an ice bath. Then, a DCM solution (2 ml) of acryloyl chloride (120 mg, 1.32 mmol, 1.1 eq) was added dropwise at zero degrees and stirred overnight at room temperature. The solution was washed with 0.1 N HCl, and then EA was added for extraction, and then petroleum ether and EA were used for column chromatography to purify 100 mg of T14 (white solid).

[0231] 1H NMR(400MHz,Chloroform-d)δ8.41(d,J=2.3Hz,1H),7.64(d,J=2.4Hz,1H),7.56(d,J=1.7Hz,4H), 7.46-7.40(m,2H),7.28(s,1H),7.26(s,1H),6.63(dd,J=16.8,10.6Hz,1H),6.41(s,1H),6.33(dd, J=16.8,1.9Hz,1H),5.74(dd,J=10.6,1.9Hz,1H),4.93(d,J=13.4Hz,1H),4.21(d,J=13.7Hz,1H), 3.26(t,J=13.2Hz,1H),2.98-2.69(m,2H),2.41(s,3H),2.04(d,J=13.1Hz,2H),1.86-1.67(m,2H).

[0232] Referring to the synthesis method of compound T14, the following compounds were synthesized:

[0233]

[0234]

[0235] Example 6

[0236] Compound T16 synthesized by the present invention:

[0237]

[0238] The synthetic route is as follows:

[0239]

[0240] The experimental process is as follows:

[0241] (1) Synthesis of T16-1

[0242] Compound T24-4 (600 mg, 1.0 eq), 3-pyridine boronic acid (179 mg, 1.1 eq), K3PO4 (844 mg, 3.0 eq), Pd2(dba)3 (121 mg, 0.10 eq), PCy3 (89 mg, 0.24 eq) were dissolved in 1,4-dioxane (6 mL) and H2O (0.6 mL), replaced with N2, heated to 100 ° C, and stirred overnight. TLC showed that the raw material reaction was complete, diatomaceous earth was filtered, and the sample was spin-dried and mixed, and then column chromatography was performed to obtain T16-1 (412 mg).

[0243] (2) Synthesis of T16-2

[0244] T16-1 (412 mg) was dissolved in dichloromethane (4 mL) and 1,4-dioxane hydrochloride (8 ml), and the N2 was replaced. The reaction was carried out at room temperature for about 3 h. TLC showed that the reaction of the raw material was complete. The solvent was dried to obtain the crude product T16-2 (412 mg).

[0245] (3) Synthesis of T16

[0246] The crude product T16-2 (412 mg, 1.0 eq) was dissolved in a dichloromethane solution (2 mL), TEA (378.4 mg, 3.0 eq) was added under ice bath conditions, and a mixed solution containing acryloyl chloride (123.6 mg, 1.1 eq) and dichloromethane (2 mL) was slowly added dropwise under the protection of N2, and then the reaction was restored to room temperature for about 4 hours. LCMS showed that the reaction of the raw material was complete. The sample was spin-dried and mixed, and then column chromatography was performed to obtain T16 (212 mg).

[0247] 1 H NMR (400MHz, Chloroform-d) δ8.80 (s, 1H), 8.64-8.58 (m, 1H), 8.41 (d, J = 2.3Hz, 1H), 7.84 (dt, J = 7. 9,1.9Hz,1H),7.66-7.55(m,5H),7.40(dd,J=7.9,4.8Hz,1H),6.64(dd,J=16.8,10.5Hz,1H),6.52(s ,1H),6.33(dd,J=16.9,1.9Hz,1H),5.74(dd,J=10.5,1.9Hz,1H),4.94(d,J=13.4Hz,1H),4.23(d,J =13.8Hz,1H),3.28(t,J=12.9Hz,1H),2.94-2.76(m,2H),2.07(d,J=13.4Hz,2H),1.35-1.25(m,2H).

[0248] Referring to the synthesis method of compound T16, the following compounds were synthesized:

[0249]

[0250]

[0251] Example 7

[0252] Compound T26 synthesized by the present invention:

[0253]

[0254] The synthetic route is as follows:

[0255]

[0256] The experimental process is as follows:

[0257] (1) Synthesis of T26-2

[0258] Add T26-1 (2 g, 7.41 mmol, 1.0 eq), p-trifluorophenol (1.44 g, 8.89 mmol, 1.2 eq), CS2CO3 (4.8 g, 14.81 mmol, 2 eq), TMEDA (86 mg, 0.74 mmol, 10% eq), CuI (140 mg, 0.74 mmol, 10% eqiv) and 20 ml DMSO solution into a microwave tube in sequence, and heat to reflux at 110°C for 20 h.

[0259] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was purified by column chromatography to obtain 1.9 g of T26-2.

[0260] (2) Synthesis of T26-3

[0261] T26-2 (1.97 g, 5.64 mmol, 1.0 eq), pinacol borate (2.09 g, 6.77 mmol, 1.2 eqiv), potassium carbonate (1.56 g, 11.28 mmol, 2.0 eqiv) water / 1,4-dioxane (1 / 10) (1.9 mL / 19 mL), Pd(dppf)Cl2 (206.4 mg, 0.282 mmol, 5% eq) were added to a 100 mL single-mouth bottle in sequence. After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 16 hours. After the reaction was completed and cooled to room temperature, EA was diluted with diatomaceous earth, filtrated, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by spinning through a column to obtain 2.1 g of T26-3 (light yellow solid).

[0262] (3) Synthesis of T26-4

[0263] T26-3 (2.1 g) was dissolved in ethanol (30 mL), triphenylphosphine rhodium chloride (450 mg, 20%) was added, and the mixture was reacted under high pressure hydrogen for 24 h. If the raw material was not completely reacted, 1.9 g of T26-4 (white solid) was obtained after column purification.

[0264] (4) Synthesis of T26-5

[0265] T26-4 (1.1 g, 2.41 mmol, 1.0 eq), S2 (1.25 g, 6.03 mmol, 2.5 eq), NaHCO3 (911 mg, 10.85 mmol, 4.5 eq), Pd(OAC)2 (54 mg, 0.24 mmol, 0.1 eq) and PCy3 (135.2 mg, 0.48 mmol, 0.2 eq) were added to the reaction flask, and the solvent was added with 1,4-dioxane / EtOH / water (7:2:1) (7 ml / 2 ml / 1 ml). After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed, the mixture was cooled to room temperature and 20 mL of water was added. The mixture was extracted with ethyl acetate (25 ml*3). The organic layers were combined and washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and dried by column to obtain 1.1 g of product T26-5.

[0266] (5) Synthesis of Compound T26-6

[0267] Compound 5 (1.1 g) was added to DCM (10 ml), and then HCl / dioxane (20 mL, 4 M) was added, and then reacted at room temperature overnight. After direct spin drying, 900 mg of white solid 6 was obtained.

[0268] (6) Synthesis of Compound T26

[0269] Compound T26-6 (820 mg, 2.03 mmol, 1.0 eq), triethylamine (615.1 mg, 6.09 mmol, 3.0 eq), DCM (8 ml) were added to a reaction flask, and then a DCM solution (6 ml) of acryloyl chloride (202.11 mg, 2.33 mmol, 1.1 eq) was added dropwise at zero degree, and stirred at room temperature overnight. The solution was washed with 0.1 N HCl, and then EA was added for extraction, and then petroleum ether and EA were used for column chromatography to purify 170 mg of T26 (white solid).

[0270] 1H NMR(400MHz,Chloroform-d)δ8.38(s,1H),8.05(s,1H),7.67(d,J=8.2Hz,2H),7.40(s, 1H),7.21(s,2H),6.63(dd,J=16.9,10.8Hz,1H),6.49(s,1H),6.31(d,J=16.8Hz,1H),5 .71(d,J=10.6Hz,1H),4.88(d,J=13.1Hz,1H),4.16(d,J=13.8Hz,1H),3.96(s,3H),3.2 4(d,J=12.7Hz,2H),2.77(t,J=13.0Hz,1H),2.05(d,J=13.1Hz,2H),1.90-1.78(m,2H).

[0271] Referring to the synthesis method of compound T26, the following compounds were synthesized:

[0272]

[0273]

[0274]

[0275]

[0276] Example 8

[0277] Compound T28 synthesized by the present invention:

[0278]

[0279] The synthetic route is as follows:

[0280]

[0281] The experimental process is as follows:

[0282] (1) Synthesis of T28-2

[0283] 1,2-Dibromoethane (78.5 mg, 0.418 mmol, 0.1 eq) was added to a THF solution of zinc powder (410.7 mg, 6.27 mmol, 1.5 eq), heated to reflux for 1 h, cooled to room temperature, trimethylsilyl chloride (45.4 mg, 0.418 mmol, 0.1 eq) was added dropwise, stirred for 1 h, and then a THF solution of trifluoromethylbenzyl bromide (1 g, 4.18 mmol, 1 eq) was added dropwise, reacted at 60°C for 1 h, cooled to room temperature, T28-1 (1.36 g, 5.02 mmol, 1.2 eq) and Pd(phh3)4 (97 mg, 0.084 mmol, 0.02 eq) were added, heated to reflux for 1 h, and finally stirred at room temperature for 18 h. After the reaction, the mixture was filtered through celite and quenched with EA and aqueous sodium carbonate solution. The solid precipitated and the filtrate was filtered and extracted with water and EA. The mixture was washed once with saturated NaCl and dried over anhydrous sodium sulfate. The mixture was concentrated and passed through a column to obtain 600 mg of T28-2.

[0284] 1 H NMR (400MHz, Chloroform-d) δ8.47(d,J=2.2Hz,1H),7.88(d,J=2.2Hz,1H),7.54(d,J=8.0Hz,2H),7.40(d,J=7.9Hz,2H),4.36(s,2H).

[0285] (2) Synthesis of T28-3

[0286] T28-2 (2 g, 5.731 mmol, 1.0 eq), pinacol borate (2.12 g, 6.88 mmol, 1.2 eqiv), potassium carbonate (1.58 mg, 11.46 mmol, 2.0 eqiv) water / 1,4-dioxane (1 / 10) (2 mL / 20 mL), Pd(dppf)Cl2 (209.8 mg, 0.287 mmol, 5% eq) were added in sequence in a 100 mL single-mouth bottle, nitrogen was replaced three times and the temperature was raised to 105 degrees for reaction for 16 hours. After the reaction was completed, it was cooled to room temperature and diluted with EA, filtered on diatomaceous earth, and 10 mL of water was added. It was extracted with ethyl acetate (20 ml*3), the organic layers were combined, washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and passed through a column to obtain T28-3 (2.3 g, light yellow solid).

[0287] 1H NMR(400MHz,Chloroform-d)δ8.46(d,J=2.4Hz,1H),7.51(d,J=8.1Hz,2H),7.41(d,J=2.5Hz,1H),7 .25(d,J=8.1Hz,3H),5.51(s,1H),4.18(s,2H),3.99(s,2H),3.55(s,2H),2.22(s,2H),1.50(s,9H).

[0288] (3) Synthesis of T28-4

[0289] T28-4 (200 mg, 0.4423 mmol, 1.0 eq), borate (230.1 mg, 1.11 mmol, 2.5 eq), NaHCO3 (167.2 mg, 1.99 mmol, 4.5 eq) Pd(OAC)2 (10 mg, 0.044 mmol, 0.1 eq) and PCy3 (25 mg, 0.088 mmol, 0.2 eq) were added to the reaction flask, and the solvent was added with 1,4-dioxane / EtOH / water (7:2:1) (1.4 ml / 0.4 ml / 0.2 ml). After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed, the mixture was cooled to room temperature and 10 mL of water was added. The mixture was extracted with ethyl acetate (10 ml*3). The organic layers were combined and washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, filtered and dried, and then passed through a column to obtain the product T28-4 (122 mg).

[0290] 1 H NMR(400MHz,Chloroform-d)δ8.86(d,J=2.2Hz,1H),7.85(d,J=2.2Hz,1H),7.50(d,J=8.0Hz,2H),7.42(d,J=2.3Hz,1H),7.31 -7.24(m,2H),6.57(d,J=2.3Hz,1H),5.53(d,J=29.2Hz,1H),4.24(s,2H),3.97(s,5H),3.55(s,2H),2.27(s,2H),1.51(s,9H).

[0291] (4) Synthesis of T28-5

[0292] T28-4 (1 g) was dissolved in ethanol (10 mL), and triphenylphosphine rhodium chloride (200 mg, 20%) was added. The mixture was reacted under high pressure hydrogen for 24 h. If the raw material was not completely reacted, 0.9 g of T26-5 (white solid) was obtained after column purification.

[0293] (5) Synthesis of Compound T28-6

[0294] Compound 5 (0.9 g) was added to DCM (8 ml), and then HCl / dioxane (20 mL, 4 M) was added, and then reacted at room temperature overnight. After direct spin drying, 800 mg of T28-6 was obtained.

[0295] (6) Synthesis of Compound T28

[0296] Compound T28-6 (800 mg, 2.03 mmol, 1.0 eq), triethylamine (615.1 mg, 6.09 mmol, 3.0 eq), and DCM (8 ml) were added to a reaction flask, and then a DCM solution (6 ml) of acryloyl chloride (202.11 mg, 2.33 mmol, 1.1 eq) was added dropwise at zero degree, and stirred at room temperature overnight. The solution was washed with 0.1 N HCl, and then EA was added for extraction, and then purified by column chromatography using petroleum ether and EA to obtain 100 mg of T28 (white solid). LC-MS [M+1]: 455.2

[0297] Referring to the synthesis method of compound T28, the following compounds were synthesized:

[0298]

[0299]

[0300]

[0301] Biological activity test experiment

[0302] Experimental Example 1 Cell Anti-Proliferation Experiment

[0303] Proliferation inhibition assay of YAP-TEAD inhibitor compounds on lung squamous cell carcinoma cell NCI-H226

[0304] Experimental materials and equipment: Lung squamous cell carcinoma cell NCI-H226 was purchased from Nanjing Kebai Biotechnology Co., Ltd. RPMI-1640 medium (Bio-Channel), DMSO (dimethyl sulfoxide), CCK8 (WST-8) cell analysis kit (Biyuntian), 0.25% EDTA-Tripsin (trypsin digestion solution), 1xPBS (phosphate buffer, pH 7.2), 96-well plate (Corning), fetal bovine serum (FBS), 10,000U / mL penicillin-G / streptomycin, high-speed refrigerated centrifuge (EPPENDORF 5810R), enzyme-linked immunosorbent assay (Tecan Spark).

[0305] Experimental preparation:

[0306] 1. Cell plating

[0307] A) Tumor cells were cultured at 37°C and 5% CO 2 The cells were cultured in RPMI-1640 (containing 10% FBS and 100 U / mL penicillin-G / streptomycin) under conditions of saturated humidity to 80-90% confluence.

[0308] B) Remove the culture medium from the 10 cm culture dish;

[0309] C) Rinse the cells once with 10 ml 1xPBS;

[0310] D) Add 4 ml of 0.25% EDTA-Tripsin and place in 37°C, 5% CO 2 Trypsinize in an incubator for 5 minutes, transfer to a 15 ml centrifuge tube, centrifuge at 200 g for 5 minutes, and discard the supernatant to obtain a cell pellet;

[0311] E) Resuspend in 4 ml DMEM medium, count and adjust to 10,000 cells / ml.

[0312] F) Add the cell suspension to each well of a 96-well plate at a volume of 100 μL and incubate at 37°C, 5% CO 2 Incubate overnight in an incubator.

[0313] 2. Compound treatment

[0314] Compound dilution

[0315] A) Preparation of test compound gradient dilution solutions: Prepare the test compound into a 1 mM stock solution. Then dissolve 1.5 μl of the stock solution in 1.5 ml of DMSO-free culture medium, and then perform 3-fold continuous gradient dilutions with 0.1% DMSO culture medium, for a total of 9 concentrations. The compound concentrations after dilution are as follows:

[0316] 333.33nM, 111.11nM, 37.03nM, 12.35nM, 4.15nM, 1.37nM, 0.46nM, 0.15nM

[0317] B) After thorough mixing, 100 μL of the culture compound solution was taken to replace the culture medium in the cell culture plate, with 4 replicate wells for each concentration;

[0318] C) Transfer the cells to an incubator and incubate for 3 days.

[0319] 3. CCK8 (WST-8) cell analysis

[0320] A) Take out the cell culture plate and add 10 μl of CCK-8 (WST-8) solution to each well in a biosafety cabinet;

[0321] B) Place the cell culture plate back into the incubator and continue incubating for 3 hours;

[0322] C) Select 450 nm wavelength to measure the absorbance value on TECAN enzyme-linked immunosorbent assay instrument.

[0323] 4. Data Analysis

[0324] The cell viability (%Cell Viability) was calculated using the following formula:

[0325] Cell viability (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100

[0326] A (drug added): absorbance of wells with cells, CCK8 solution, and drug solution

[0327] A (blank): absorbance of wells with culture medium and CCK8 solution but no cells

[0328] A(0 drug addition): absorbance of the well with cells, CCK8 solution and no drug solution

[0329] Cell viability: Cell proliferation activity or cytotoxic activity was obtained by curve fitting using GraphPad Prism 8 software. 50 Numeric value.

[0330] Experimental Example 2: Detection of YAP-TEAD inhibitor activity using Nano Luciferase method

[0331] (1) Experimental materials and equipment: HEK 293T cells (human embryonic kidney cells) were purchased from Nanjing Kebai Biotechnology Co., Ltd. DMEM medium (high glucose, phenol red-free, Bio-Channel), DMSO (dimethyl sulfoxide), Lipo6000 T M transfection reagent (Biyuntian), pGL3B-8xGTiiC-nLuc-CMV-fLuc plasmid, 0.25% EDTA-Tripsin (trypsin digestion solution), 1xPBS (phosphate buffer, pH 7.2), 96-well white cell culture plate (PerkinElmer), fetal bovine serum (FBS), 10,000U / mL penicillin-G / streptomycin, high-speed refrigerated centrifuge (EPPENDORF 5810R), 37°C CO 2 Incubator, Cell counter, Envision microplate reader (PerkinElmer).

[0332] Reagents

[0333] Reagent Catalog number Concentration

[0334] Nano-luciferase Assay Reagent MES pH 6.0 69892-25G 100mM

[0335] CDTA CAS:125572-95-4 1mM

[0336] Tergitol NP10-100ML 0.5%(v / v)

[0337] Mazu DF 204A8311-50ML 0.05%(v / v)

[0338] KCl CAS:7447-40-7 150mM

[0339] DTT Roche 10197777001 1mM

[0340] Thiourea T8656-50G 35mM

[0341] Furimazine 1374040-24-0 20μM Add before use

[0342] (2) Transient transfection of 293T cells

[0343] The revived 293T cells were seeded into a 10 cm culture dish and placed in a 5% CO 2 Incubate at 37°C in an incubator. To ensure transfection efficiency, cells in the logarithmic phase (cell density of about 50%-70%) should be used.

[0344] One day before transfection, the cells in the logarithmic phase were digested with Trypsin-EDTA, the culture medium was added to terminate the reaction, and the cells were mixed by pipetting to prepare a cell suspension.

[0345] Use Vi-cell to measure the cell concentration and dilute to a suspension of 5*10^5 cells per ml. After the cell suspension is prepared, gently mix it and add 10 ml of liquid to a 10 cm culture dish. In this way, the number of cells in each 10 cm culture dish is 5*10^6. 2 Culture in an incubator at 37°C for 1 day.

[0346] Take two clean sterile centrifuge tubes, add 750μL of opti-MEM Medium without antibiotics and serum to each tube, then add 15μg of plasmid (pGL3B-8xGTiiC-nLuc-CMV-fLuc) to one tube, and mix it by gently pipetting; add Lipo6000 transfection reagent to the other tube, and mix it by gently pipetting. After standing at room temperature for 5 minutes, gently add the culture medium containing DNA to the culture medium containing Lipo6000 transfection reagent, gently invert the centrifuge tube to mix, and stand at room temperature for 5 minutes.

[0347] The above mixture was evenly added dropwise to a 10 cm culture dish and replaced with fresh complete culture medium after 6 hours of culture.

[0348] (3) 96-well plate

[0349] One day after transfection, the cells were digested with Trypsin EDTA, the culture medium was added to terminate the reaction, and the cells were mixed by pipetting to prepare a cell suspension.

[0350] The cell concentration was determined using Vi-cell and diluted to a suspension of 20,000 cells per ml.

[0351] After the cell suspension is prepared, mix gently and add 100 μL to each well of a 96-well plate, so that the density of the cells to be tested is 2000 per well.

[0352] (4) Adding compound

[0353] The inoculated cell culture plate was placed in an incubator for culture, and compounds with gradient concentrations were added after about 24 hours.

[0354] The 10 mM compound stock solution was diluted to 50 μM with culture medium, and the 50 μM compound solution was added to the third column of the deep-well plate, and 216 μL of culture medium containing 0.5% DMSO was added to the fourth to eleventh columns.

[0355] Gradient dilution: pipette 100 μL of solution from the third column and add it to the fourth column. Mix well. Then pipette 100 μL of solution from the fourth column and add it to the fifth column. Repeat this operation until the eleventh column.

[0356] Using a multi-channel pipette, 25 μL of compound solution was drawn from the deep-well plate and added to a 96-well culture plate, and each compound was repeated four times on the 96-well plate. Finally, a concentration gradient of 1:3.16 with a maximum concentration of 10,000 nM was formed on the 96-well plate.

[0357] (5) Add Nano-luciferase detection reagent and read the results

[0358] 96-well plate in 5% CO 2After culturing at 37°C in an incubator for 48 hours, the cells were taken out and equilibrated at room temperature for 10 minutes.

[0359] Add 100 μL of detection reagent to each well and place it on a horizontal shaker at low speed for 10 minutes to fully lyse the cells. Use a PerkinElmer Envision microplate reader to detect the fluorescence value of each well.

[0360] (6) Result calculation

[0361] Using 0 nM as the control, the values ​​of each well were converted into percentages, and the IC was calculated by nonlinear fitting using [Inhibitor] vs. response (three parameters) in GraphPad prism software. 50 .

[0362] As shown in Table 1, where A≤100nM; 100nM <B<1μM;5μM≥C≥1μM。

[0363] Table 1

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375] "ND" means not detected.

[0376] Experimental Example 3 Pharmacokinetic Study of Drugs

[0377] Oral administration solvent: 5% DMSO + 10% Solutol HS15 + 85% saline

[0378] Preparation process for oral administration: Weigh an appropriate amount of T18 powder, add an appropriate volume of DMSO, vortex, add an appropriate volume of Solutol solution, vortex, add an appropriate amount of physiological saline, vortex and sonicate to form a uniform and clear preparation solution.

[0379] Clear solution preparation, keep 2 samples, 100μL / sample, store at 2~8℃

[0380] The animal room is equipped with an air conditioning system and is well ventilated. The indoor temperature is maintained at 20-26°C and the humidity is maintained at 40%-70%. Artificial lighting is used in the animal room, with 12 hours of light and 12 hours of dark (except for situations where working lighting is required for experimental operations and cleaning). Experimental animals are free to eat and drink.

[0381] The animals were fed normally for at least 3 days after purchase, and rats with qualified physical signs were enrolled in this experiment after veterinary examination, and each rat was marked with a tail number. The animals in the oral administration group were fasted overnight the day before administration, and resumed feeding 4 hours after administration, with free access to water.

[0382] Animal grouping and dosing

[0383]

[0384]

[0385] Notes: 1) Animals were allowed to drink water freely before and after administration; 2) All experiments were conducted according to the actual body weight of the animals.

[0386] Before administration, the state of the drug administration preparation was checked, and the uniformity of the preparation was ensured by vortexing, stirring or shaking. The theoretical administration volume for each SD rat in each group was calculated according to the following formula.

[0387]

[0388] Administration: Rats were orally administered and fasted overnight before administration.

[0389] Sample collection information

[0390]

[0391] Note: The blood collection time window for blood collection points within 1 hour (excluding the blood collection point before drug administration) is ±1 minute, and the blood collection time window for other time points is ±5%; samples are sent for testing.

[0392] Table 3

[0393]

[0394] Experimental Example 4: Thermal migration experiment of Tead protein inhibitor T18

[0395] (1) Experimental materials and equipment: Protein Thermal Shift Dye Kit, 384384-well clear plate、MicroAmp TM Optical Adhesive Film was purchased from Thermo Fisher Scientific, Multiplate TM PCR plates 96-well, clear were purchased from BIO-RAD. Human TEAD1 was purchased from sinobiological, Human TEAD2, Human TEAD3, and Human TEAD4 were purchased from WuXi AppTec (high glucose, no phenol red, Bio-Channel), DMSO (dimethyl sulfoxide), Real-Time PCR System was used for experimental testing. Protein thermal migration test dye: 40X. The amount of protein used for each test: 1μg.

[0396] Test temperature range: 25℃-99℃.

[0397] (2) Thermal migration experimental methods and processes

[0398] The reaction was subjected to four secondary pore experiments.

[0399] The in vitro protein thermal shift experimental conditions of human recombinant proteins TEAD1, TEAD2, TEAD3 and TEAD4 were set as follows:

[0400] a. TEAD protein amount per reaction: 1 μg

[0401] b. Compound T18 concentration: 12.5 μM

[0402] 2.1 Thermal shift experiment of TEADs protein

[0403] 1) Dilute the protein thermal shift dye (1000X) to 40X and prepare it for use.

[0404] 2) Place the appropriate reaction plate on ice and prepare the protein melt curve reaction.

[0405] Reaction system per well:

[0406]

[0407] 3) Pipette each reaction up and down 10 times to mix thoroughly.

[0408] 4) Use The plate was sealed with optical adhesive film, centrifuged at 1000 rpm for 1 min, and then placed on ice.

[0409] 5) Transfer the prepared plate to QuantStudio TM 7Flex, and set up the experiment as follows.

[0410] a. Experimental setup:

[0411] Instrument Type: QuantStudio TM 7Flex system; Module: 384 wells; Experiment type: melting curve; Reagents: other;

[0412] Run Instrument Properties: Fast; define Target: Reporter-ROX; Quencher-None; and set Reference Fluorescence to None.

[0413] Assign plates according to the experimental design.

[0414] b. Operation method:

[0415] Reaction volume per well: 10 μL; Reaction steps: Step 1: 25°C for 2 min, Step 2: 1.6°C / s, 99°C for 2 min; Filter selection: x1-m3

[0416] c. Start the run and save the .EDS file.

[0417] 6) Protein Thermal Shift TM Software to analyze data.

[0418] 2.2 Data Analysis

[0419] Protein Thermal Shift TM The software analyzes the EDS file of the results. The melting temperature (Tm) is obtained from the melting curve, and the migration change of Tm is calculated, and the fluorescence graph and derivative graph are exported at the same time.

[0420] 3. Results

[0421] The results of T18 on the Tm changes of human TEAD1, TEAD2, TEAD3 and TEAD4 proteins are as follows Figure 1 , as shown in Table 4 and Table 5.

[0422] Table 4: Tm values ​​of human TEAD protein alone or in the presence of T18

[0423] Tm Mean (°C) human TEAD1 human TEAD2 human TEAD3 human TEAD4 DMSO 65.0 48.4 59.4 46.6 T18 72.9 48.1 60.2 46.0

[0424] Table 5: ΔTm values ​​of human TEAD protein alone or in the presence of T18

[0425] ΔTm (°C) human TEAD1 human TEAD2 human TEAD3 human TEAD4 T18 7.8 -0.3 0.8 -0.6

[0426] 4. Summary and discussion

[0427] Under this experimental condition, T18 changed the Tm values ​​of all four TEAD family member proteins compared with DMSO, but a greater effect was observed on TEAD1, indicating that T18 is a selective inhibitor of TEAD1 protein.

[0428] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof, in, X1, X2, X3, and X4 are each independently selected from the following group: CR, N; R is independently selected from the group consisting of H, halogen, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl; A is selected from the following group: B is selected from the following group: L is selected from the group consisting of NR4, O, S, Se, sulfoxide, sulfone, CR2R3; R1 is selected from the group consisting of H, CF3, CF2H, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethoxy, SF5, tert-butyl; R2 is independently selected from the following group: H, halogen, CN, NH2, hydroxyl, ester group, urea group, carbamate group, amide group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, among which NH2, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 The hydrogen in the cycloalkoxy, aryl and heteroaryl groups can be arbitrarily substituted, and the substituents are halogen, CN, NH2, hydroxyl, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, or R2 and the structure to which it is connected form a 3-7 membered ring, or different R2s form a 3-7 membered ring; R3, R4, and R5 are each independently selected from the group consisting of H, F, methyl, and CN; m is each independently selected from the following group: 0, 1, 2, 3, 4, 5, 6.

2. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: m is selected from the following group: 0, 1, 2, 3.

3. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: The compound is shown in Formula II, Formula III, or Formula IV: Wherein, X2, A, B, L, and R1 are as defined in claim 1.

4. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: A is selected from the following group: B is selected from the following group: R2, R3, R4, R5 and m are as defined in claim 1.

5. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: B is selected from the following group: R2, R3, R4, R5 and m are as defined in claim 1.

6. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: The compound is selected from the group consisting of:

7. A pharmaceutical composition, characterized in that It comprises a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound according to claim 1 or 6 or a pharmaceutically acceptable salt, solvate or prodrug thereof.

8. Use of the pharmaceutical composition according to claim 7, characterized in that: Used for preparing a medicament for preventing and / or treating a proliferative disease.

9. Use of the pharmaceutical composition according to claim 7, characterized in that: For use in the preparation of a medicament for use selected from the group consisting of: 1) Prevent and / or treat diseases caused by abnormal activity of YAP / TEAD; 2) Prevent and / or treat diseases caused by Hippo pathway dysregulation; 3) Prevent and / or treat diseases related to YAP or TAZ or YAP / TAZ or TEAD or YAP / TEAD or YAP / TAZ / TEAD dysregulation.

10. A combination of a compound according to claim 1 or 6 or a pharmaceutically acceptable salt, solvate or prodrug thereof and a second drug, characterized in that: For the prevention and / or treatment of cancer; The second drug is selected from the group consisting of ERK inhibitors, MEK inhibitors, KRAS inhibitors, BRAF inhibitors, EGFR inhibitors, Wnt inhibitors, and PD-1 inhibitors.